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Farnesyltransferase inhibitors (FTIs), developed as anti-cancer drugs, have the potential to modulate immune
responses without causing nonspeciﬁc immune suppression. We have investigated the possibility that FTIs,
by affecting T cell cytokine secretion, can attenuate alloreactive immune responses. The effects of FTIs on
murine alloreactive T cells were determined both in vitro, by measuring cytokine secretion or cell
proliferation in mixed lymphocyte cultures, and in vivo, by performing skin allografts from H-2bm12 mice to
MHC class II-disparate B6 mice. We found that two different FTIs, ABT-100 and L-744,832, blocked secretion
of IFN-γ, IL-2, IL-4, and TNF-α from naïve T cells in vitro. ABT-100 and L-744,832 blocked cytokine production
from both CD4+ and CD8+ naïve T cells stimulated with CD3 and CD28 antibodies, but only if the cells were
pretreated with the FTIs for 48 h. Proliferation of alloreactive T cells in mixed lymphocyte cultures was
blocked by either FTI. We also found that the proliferation of enriched T cells stimulated with IL-2 was
blocked by ABT-100 treatment. In mice with an MHC class II-disparate skin graft, rejection of primary
allografts was signiﬁcantly delayed by treatment with either ABT-100 or L-744,832. Secondary rejection in
mice previously primed to the alloantigen was found to be unaffected by L-744,832 treatment. We have
shown that FTIs can block T cell cytokine secretion and attenuate alloreactive immune responses. The ability
of FTIs to block secretion of cytokines, including IFN-γ and IL-4, from naïve T cells provides a likely biological
mechanism for the speciﬁc suppression of class II MHC-mediated allorejection. These results demonstrate
that FTIs may have useful immunomodulatory activity due to their ability to delay priming to alloantigens.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Farnesyltransferase inhibitors (FTIs) were developed to block the
function of proteins involved in oncogenic signaling by preventing
their proper localization. The enzyme farnesyltransferase attaches a
prenyl group to at least 17 cellular proteins, includingH-Ras, K-Ras, and
N-Ras, and this post-translational modiﬁcation is necessary for the
proper subcellular targeting and function of these substrate proteins
[1]. The anti-neoplastic activity of FTIs does not depend on the
presence of activated Ras oncogenic proteins and the activity of these
drugs likely depends on their combined inhibitory effects on several
farnesylated proteins.Wehave recently shown that FTIs are effective in
a mouse model of mature B cell lymphoma [2], a tumor that depends
on antigen receptor signaling for neoplastic growth [3]. Early clinical
trials have shown that FTIs may be effective in treating hematologic
malignancies and Phase III trials are ongoing for these diseases [4].
This study utilizes two structurally unrelated FTIs, L-744,832 and
ABT-100. L-744,832 is a peptidomimetic inhibitor that has been shown
to affect the growth and survival of tumor cells both in vitro [5–7] and
in mouse models [8–14]. ABT-100 has been shown to have anti-
neoplastic activity in xenografts of human cancer cell lines and in
animal models [15–17]. This activity may be due, in part, to anti-
angiogenic effects of ABT-100 [16] related to its ability to block VEGF
expression [17]. Because ABT-100 and L-744,832 are not structurally
related to each other, they are unlikely to share similar nonspeciﬁc
effects.
Although FTIs are not known to generally suppress immune
responses, several studies have suggested that they may have speciﬁc
immunomodulatory activity [18–24]. FTIs do not appear to block
lymphocyte activation by antigen. For example, we have found that
the proliferation ofmurine primary B cells stimulatedwith anti-IgM and
anti-CD40 is unaffected by concentrations of L-744,832 that block the
proliferation of a B cell lymphoma [2]. The ability of HMG-CoA reductase
inhibitors to block cardiac rejection and allo-antibody production in
humans [25,26], ﬁrst suggested that prenylated proteins may be
important for allorejection (reviewed in [27]). Several farnesylated
proteins are known to be involved in lymphocyte signaling, such as Ras,
RhoB, and Rheb [1]. Inhibition of Ras can block IL-2 production in
activated lymphocytes [28], but a Ras-independent pathway for IL-2
production has also been described [29]. A prenylation inhibitor that
blocks both farnesylation and geranylgeranylation, L-778,123, can
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prevent IL-2-mediatedproliferation of lymphocytes, but has no effect on
IL-2 secretion [23]. FTI treatment can block secretion of inﬂammatory
cytokines from monocytes or macrophages [18,20] as well as Th1 and
Th2 cytokines frommurine T cell clones [21]. The inhibition of cytokine
secretion from Th1 and Th2 cell clones does not depend on Ras/MAP
kinase inhibition but, rather, is due to a post-transcriptional block of
cytokine synthesis [21]. In a human cancer cell line, the SCH66336 FTI
has been shown to block mTOR signaling by blocking the farnesylation
of Rheb [30]. It appears that ABT-100 may act through a similar
mechanism to block the activation of p70S6 kinase, therebyaffecting the
translation of certain mRNAs, including those for certain cytokines. If
FTIs can block secretion of certain cytokines under speciﬁc conditions,
then this could explain their ability to affect particular immune
responses without general immune suppression.
FTIs could be clinically useful as immunomodulators by affecting
cytokine secretion from alloreactive T cells. The ABT-100 FTI has been
shown to delay rejection of rat cardiac allografts mismatched at both
class I and class II MHC [24], demonstrating that FTIs can affect
alloreactive immune responses in a non-stringent rejection model.
Cytokines are responsible for regulating the tolerance or rejection of
allografted organs at several steps of the alloreactive immune
response [31]. Manipulation of the balance of cytokines may make it
possible to promote the tolerance of allografts without nonspeciﬁc
immune suppression.
2. Objective
The possibility that FTIs can modulate immune responses, such as
allorejection, requires further investigation. The goals of this study
were to determine if FTIs could block cytokine secretion from
alloreactive T cells and delay an alloreactive immune response.
3. Materials and methods
3.1. Mice and reagents
C57BL/6 mice (B6) were purchased from Charles River Labora-
tories. BALB/c and B6-H2-Ab1bm12 mice (bm12) were purchased from
The Jackson Laboratory. All procedures involving animals were
reviewed and approved by the Bucknell University IACUC. L-744,832
(BIOMOL) was dissolved at 2.5 mg/ml in DMSO and stored for nomore
than 1 mo at −80 °C prior to use in tissue culture experiments. For
treatment of mice, L-744,832 was dissolved at 2.5 mg/ml in HBSS
(Sigma), sterilized by ﬁltration, and stored at −80 °C for no more than
Fig.1. Effects of FTIs on cytokine secretion from antibody-stimulated Tcells. Cytokine secreting cells were detected using ELISPOTassays for IFN-γ (a), IL-2 (b), IL-4 (c), or TNF-α (d). B6
splenocytes (1×106 cells/ml) were treated with the indicated concentration of ABT-100 or L-744,832 beginning 24 h before stimulation. ELISPOT assays were then performed on
1×105 cells/well stimulated with 5 μg/ml anti-CD3 and 10 μg/ml anti-CD28 for 24 h (a) or 48 h (b–d). For each condition, the mean and standard deviation are shown for triplicate
samples. An asterisk indicates a statistically signiﬁcant difference between the sample and untreated cells as determined by Student's t test (pb .05).
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1 wk prior to i.v. injection b.i.d. at 20 mg/kg. ABT-100, generously
provided by Abbott Laboratories, was dissolved at 10 mg/ml in DMSO
and stored at −20 °C prior to use in tissue culture experiments. For
treatment of mice, ABT-100 was partially dissolved in ethanol at a
concentration of 50 mg/ml, then diluted to 0.625 mg/ml in 0.5%
hydroxypropylmethylcellulose (HPMC). The solutionwas adjusted to a
pH of 3.5 and brought to a ﬁnal concentration of 1% ethanol, 0.4%
HPMC and 0.5 mg/ml ABT-100. The solution was stored at room
temperature for no more than 2 weeks and provided to mice ad
libitum as drinking water. This concentration of ABT-100 in drinking
water was determined to administer an average of 100 mg/kg/day of
the drug in separate experiments (data not shown).
3.2. ELISPOT assays
Splenocytes were isolated from B6 mice by macerating spleens,
treating with RBC Lysis Buffer (Biolegend), and resuspending in
complete RPMI media (RPMI 1640 (Mediatech) with 10% heat-
inactivated FBS (PAA North America)). Cells at either 1×106 or
2×107 cells/ml were treated with ABT-100 or L-744,832 beginning
24 h prior to stimulation either with 5 μg/ml anti-CD3ε and 10 μg/ml
anti-CD28 (Biolegend) or with allogeneic cells. BALB/c or bm12
stimulator cells were prepared by treating splenocytes for 20 min
with 50 μg/ml mitomycin C (Sigma). Stimulator cells at 4×106 cells/ml
were either used fresh or cryopreserved prior to use. ELISPOT kits from
eBioscience were used according to the manufacturer's instructions.
IFN-γwasmeasured for 24 h and IL-2, IL-4, and TNF-αwere measured
for 48 h. Data was blinded prior to manual spot counting.
3.3. Flow cytometry
Splenocytes were incubated in complete RPMImedia at 1×106 cells/
ml in the presence or absence of ABT-100 or L-744,832. Cells were
stimulated by the addition of 5 μg/ml anti-CD3ε and 10 μg/ml anti-CD28.
For intracellular cytokine labeling, cells were treated with 3 μg/ml
brefeldin A (eBiosciences) for theﬁnal 4 h of stimulation. Cellswere then
blocked with anti-CD16/32 and labeled with ﬂuorescent anti-CD4 and
anti-CD8. Cells were ﬁxed and permeabilized with Cytoﬁx/cytoperm
buffer (BD Biosciences) and then labeledwith ﬂuorescent anti-TNF-α or
anti-IFN-γ antibodies (Biolegend). Flow cytometry was performed on a
BD FACScan using Cellquest software for data acquisition and analysis.
3.4. Proliferation assays
Total splenocytes or splenocytes enriched for T cells by negative
selection paramagnetic beads (Invitrogen) from B6 mice were
suspended at 2×106 cells/ml and treated with ABT-100 beginning
24 h prior to stimulation. Cells were then stimulated either with 5 μg/
ml anti-CD3ε and 10 μg/ml anti-CD28 or with 2 ng/ml (~10 U/ml)
murine IL-2 (Peprotech). For mixed lymphocyte cultures (MLCs), B6
responder cells were stimulated with mitomycin C-treated BALB/c
cells. For 3H-thymidine measurements, samples were stimulated for
Fig. 2. Effects of FTIs on production of TNF-α and IFN-γ in CD4+ and CD8+ T cells. Intracellular cytokine staining was used to measure TNF-α and IFN-γ production in brefeldin A-
treated cells. Splenocytes at 1×106 cells/ml were treated with 1.0 μMABT-100 (b, e, and h), 10 μM L-744,832 (c, f, and i), or left untreated (a, d, and g). Cells were stimulated with 5 μg/
ml anti-CD3 and 10 μg/ml anti-CD28 either 44 h later (a–f) or 24 h later (g–i). Brefeldin A was added 44 h after FTI treatment and 4 h later cells were stained with ﬂuorescent
antibodies and analyzed by ﬂow cytometry. The percentage of viable cells in selected quadrants is shown.
165A.E. Gaylo et al. / Transplant Immunology 20 (2009) 163–170
72 h and then 5 μCi 3H-methyl thymidine (Sigma) was added and
thymidine incorporationwas measured 18 h later by ﬁlter binding. For
BrdU measurements, after 36 h of stimulation, BrdU was added for
24 h and incorporation was quantiﬁed using an ELISA kit (Roche
Diagnostics).
3.5. Skin allografts
Skingraftswereperformedusing full thickness tail skin (~0.5×1.0 cm)
from bm12mice or B6mice onto the dorsal trunk of B6 recipients. Seven
days after surgery, bandages were removed and grafts were scored daily
for rejection, which was considered complete when N90% of the donor
tissue was necrotic.
4. Results
To determine whether FTI treatment could block the secretion of cytokines from
naïve T cells when activated, we performed ELISPOT assays on murine splenocytes in
culture. Splenocytes were harvested from B6 mice, treated with 0 to 1 μM ABT-100 or 1
to 10 μM L-744,832 and transferred to ELISPOT plates after 24 h. Antibodies to CD3 and
CD28 were then used to stimulate T cells and cytokine production was measured
(Fig. 1). Unstimulated cells did not secrete cytokines and CD3/CD28 stimulation
promoted secretion of IFN-γ, IL-2, IL-4, and TNF-α. FTI treatment decreased the number
of cytokine secreting cells for all four cytokines measured. The largest effect on cytokine
secretion was seen with 1 μM ABT-100, where the treated cells were detected secreting
cytokines at levels between 14% and 29% of the untreated cells. Either ABT-100 or L-
744,832 treatment signiﬁcantly blocked the secretion of each of these cytokines at both
concentrations tested.
The results shown in Fig. 1 would be expected if the FTIs were causing cell death at
the concentrations tested. To determine if these concentrations of ABT-100 or L-744,832
were cytotoxic, we measured cell death and T cell activation under the same conditions
used for the ELISPOT measurements. We found that viability decreased between 5 and
15% with ABT-100 or L-744,832 treatment (unpublished results). T cell activation, as
measured by CD25 expression was also not substantially affected by treatment with
ABT-100 or L-744,832 (unpublished results). Together, these two results demonstrate
that the concentrations of either ABT-100 or L-744,832 that were able to block the
secretion of Th1 and Th2 cytokines did not block activation of T cell signaling or cause
cell death.
To determine if the production of cytokines in both CD4+ and CD8+ T cells were
affected by FTI treatment, we used intracellular cytokine staining tomeasure TNF-α and
IFN-γ (Fig. 2). Splenocytes were treated with 1.0 μM ABT-100 or 10 μM L-744,832 or left
untreated. For TNF-αmeasurements, after 48 h of FTI treatment, cells were stimulated
with anti-CD3/anti-CD28 for 4 h. For IFN-γ measurements, after 24 h of FTI treatment,
cells were stimulated with anti-CD3/anti-CD28 for 24 h. Brefeldin A was used to block
cytokine secretion for the ﬁnal 4 h of stimulation. Following brefeldin A treatment, cells
were labeled with CD4 and CD8 ﬂuorescent antibodies, ﬁxed, permeabilized, and then
stained with a ﬂuorescent antibody to the appropriate cytokine. We found that TNF-α
was produced by both CD4+ and CD8+ T cells (Fig. 2a and d) and that IFN-γ was
produced predominantly by CD8+ T cells (Fig. 2g). When the cells were treated with
ABT-100 or L-744,832, we found that the amount of cytokine produced decreased
substantially in both CD4+ and CD8+ T cells (Fig. 2). These results demonstrate that
production of cytokines in both CD4+ and CD8+ naïve Tcells is sensitive to FTI treatment.
We conﬁrmed that the effects of ABT-100 or L-744,832 on cytokine secretion
required preincubation of the cells with FTI. When we measured TNF-α in T cells that
were stimulated immediately after FTI addition (Fig. 3), we found that neither ABT-100
nor L-744,832 blocked production of the cytokine. The inhibitory effects of FTI
Fig. 3. Effects of FTIs on production of TNF-α in T cells without pretreatment. Intracellular cytokine staining was used to measure TNF-α production in brefeldin A-treated cells.
Splenocytes at 1×106 cells/ml were left untreated (a), treated with 1.0 μMABT-100 (b), or treated with 10 μM L-744,832 (c). At the same time, cells were stimulated with 5 μg/ml anti-
CD3 and 10 μg/ml anti-CD28 and Brefeldin A was added. After 4 h, cells were stained with ﬂuorescent antibodies and analyzed by ﬂow cytometry. The percentage of viable cells in
selected quadrants is shown.
Fig. 4. Effects of FTIs on cytokine secretion from alloreactive T cells. B6 splenocytes at
2×107 cells/ml were treated with ABT-100 beginning 24 h before stimulation and then
2×106 cells/well were stimulated with 4×105 mitomycin C-treated BALB/c or bm12
splenocytes for 24 h (a) or 48 h (b). Cytokine secreting cells were detected using ELISPOT
assays for IFN-γ (a) or IL-4 (b). For each condition, the mean and standard deviation are
shown for triplicate samples. An asterisk indicates a statistically signiﬁcant difference
between the sample and untreated cells as determined by Student's t test (pb .05).
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treatment required incubation of the cells for at least 48 h (unpublished results),
presumably because protein turnover of farnesylated proteins is necessary.
ELISPOTs on MLCs were used to determine if the ABT-100 FTI could block cytokine
secretion from naïve, alloreactive T cells. B6 splenocytes, treated with 0 to 1 μM ABT-
100, were stimulated with mitomycin C-treated cells from either BALB/c mice, which
are fully MHC mismatched, or bm12 mice, which have a single class II MHC mismatch
(Fig. 4). We measured secretion of the Th1 cytokine, IFN-γ, after 24 h and the Th2
cytokine, IL-4, after 48 h. The allogeneic cells caused secretion of IFN-γ and IL-4 from
untreated responder splenocytes. ABT-100 at 1.0 μM signiﬁcantly blocked secretion of
both of these cytokines from class II-disparate alloreactive T cells and secretion of IFN-γ
from class I/II-disparate alloreactive T cells.
We next measured proliferation in MLCs to determine if the block in cytokine
secretion by ABT-100 could affect the cytokine-dependent proliferation of alloreactive T
cells. B6 splenocytes were stimulated with mitomycin C-treated BALB/c cells and
proliferation was measured by 3H-thymidine incorporation (Fig. 5a). Treatment of the
responder cells with 0.1 μMor greater ABT-100 signiﬁcantly blocked the proliferation of
the alloreactive T cells stimulated by BALB/c cells. This block in proliferation was
accompanied by a smaller decrease in cell viability at the highest concentration of ABT-
100 tested (unpublished results), but the block in proliferation was much greater than
the decrease in viability.
The decreased proliferation of FTI-treated alloreactive T cells could be caused by
blocking the secretion of cytokines or by inhibiting themitogenic effects of cytokines on
lymphocytes. To determine if cytokine-stimulated cell proliferation was blocked by
ABT-100 treatment, we measured T cell proliferation induced by IL-2 (Fig. 5b). B6
splenocytes were enriched for T cells by negative selection and then treated with 0 to
10 μM ABT-100. After 24 h, the T cells were then stimulated with 2 ng/ml murine IL-2
and proliferation was measured by BrdU incorporation. For comparison, we separately
stimulated cells with CD3/CD28 antibodies. Both IL-2 and antibody stimulation caused
proliferation of the puriﬁed T cells, and this proliferation was signiﬁcantly blocked by
treatment with ABT-100. Higher doses of ABT-100 were required to maximally block
proliferation induced by IL-2, but both stimuli were inhibited similarly by 1 μMABT-100
(Fig. 5b). Together with the previous data, this demonstrates that FTI treatment can
both block the secretion of cytokines and block the proliferative response of T cells to
mitogenic cytokines.
Fig. 5. Effects of ABT-100 on proliferation of T cells in vitro. (a) Proliferation of
alloreactive T cells in MLCs was measured using 3H-thymidine incorporation. B6
splenocytes at 2×106 cells/ml were treated with the indicated concentration of ABT-100
and then stimulated with 4×106 cells/ml mitomycin C-treated BALB/c stimulator cells.
After 72 h of stimulation 3H-thymidine incorporation was measured for 18 h by ﬁlter
binding. Proliferation is shown relative to cells stimulated with allogeneic cells but not
treated with ABT-100. (b) Proliferation of puriﬁed T cells stimulated with antibodies or
with IL-2 was measured using BrdU incorporation. T cells were puriﬁed from B6
splenocytes by negative selection. The enriched T cells at 2×106 cells/ml were treated
with the indicated concentration of ABT-100 for 24 h and then 2×105 cells/well were
stimulated for 60 h with 5 μg/ml anti-CD3 and 10 μg/ml anti-CD28 or with 2 ng/ml
murine IL-2. During the last 24 h of stimulation BrdU incorporationwas measured with
a colorimetric assay. Proliferation is shown relative to cells stimulated with antibodies
or with IL-2 but not treated with ABT-100. For each condition, the mean and standard
deviation are shown for triplicate samples. An asterisk indicates a statistically
signiﬁcant difference between the sample and untreated cells as determined by
Student's t test (pb .05).
Fig. 6. Effects of FTIs on skin allograft rejection in primary responses. Skin allografts
were performed using full thickness tail skin from bm12 donor mice onto the trunks of
B6 mice. (a) Four transplant recipients were left untreated and 5 recipients were treated
orally with 100 mg/kg/day ABT-100 beginning 2 days prior to surgery. (b) Eight
transplant recipientmice were treated with 40mg/kg/day L-744,832 i.v. for 7 days and 7
recipients were left untreated. Control B6 mice that received syngeneic skin grafts from
B6 donor mice are shown for comparison.
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To test if FTI treatment could affect an alloreactive immune response in vivo, we
measured the effects of ABT-100 or L-744,832 treatment on rejection of class II MHC
mismatched skin allografts in mice. Shown in Fig. 6a, 5 B6 mice were treated
continuously with 0.5 mg/ml ABT-100 in their drinking water (~100 mg/kg/day)
beginning 2 days before surgery. Full thickness tail skin from a bm12 mouse was
engrafted onto the trunks of these mice and 4 untreated B6 mice. The mean graft
survival time for the untreated mice was 13.8±1.5 days and was 38.4±23.0 days for the
mice treated with ABT-100 (Fig. 6a). We also determined if the L-744,832 FTI could
delay skin allograft rejection (Fig. 6b). Intravenous treatment twice daily with ~40 mg/
kg/day L-744,832 began the day after surgery and continued for 7 days. The mean graft
survival time for the 7 untreated mice was 12.8±3.8 days and was 26.4±14.2 days for
the 8 mice treated with L-744,832. Both ABT-100 and L-744,832 treatments cause
signiﬁcant delays (pb .05) in the rejection of class II MHC mismatched skin allografts on
naïve mice.
We next performed second set grafts to determine if the effects of FTI treatment on
allograft rejection could also delay rejection mediated by T cells primed to the class II
alloantigen (Fig. 7). Skin allograft surgeries using bm12 tail skin were performed on a
cohort of B6 mice and rejection was allowed to occur without FTI treatment.
Approximately 4 weeks later, a second bm12 skin allograft was performed on the
opposite side of the trunk of eachmouse. A group of 6micewere treated with L-744,832
as above for 7 days beginning the day after the second surgery and 7 mice were left
untreated. The mean graft survival time for the untreated mice was 9.7±1.6 days and
was 10.5±1.8 days for the treated mice. The difference between these rejection times
was not signiﬁcant. Under the same conditions that L-744,832 delayed primary allograft
rejection, this FTI did not affect allograft rejection in mice previously primed with the
mismatched class II MHC alloantigen.
5. Discussion
5.1. Speciﬁcity of FTIs
By demonstrating that FTIs could affect alloreactive immune
responses in vitro and in vivo, we have provided evidence that FTIs
could be useful immune modulators. We used two different,
structurally unrelated, FTIs for several of the experiments (Figs. 1–3
and 6) to establish that the effects we observed were speciﬁc to the
inhibition of farnesyltransferase. FTIs can have off-target effects,
including proteasome inhibition [32], but the observation that
multiple FTIs exhibit the same effect increase the likelihood that the
effects are due to the inhibition of prenylation. A previous study on
cytokine secretion by murine Th1 and Th2 clones, showed that ﬁve
different FTIs, including L-744,832, could block cytokine secretion
[21].
The delay between FTI treatment and the effects that we have
observed is consistent with the hypothesis that protein prenylation is
the target of FTI treatment. Because farnesylation is an irreversible
modiﬁcation within the cell, protein turnover is required before the
function of modiﬁed proteins is blocked. In this study, when we
examined the effects of pretreating cells with FTIs for less than 24 h,
we did not observe inhibition of cytokine production (Fig. 3).
At high doses, FTIs are known to inhibit geranylgeranyltransferase I
[1], a prenylation enzyme closely related to farnesyltransferase. For
our in vitro experiments, signiﬁcant effects were observed at FTI
concentrations that are not known to block geranylgeranyltransferase.
For example, in tissue culture experiments the ABT-100 FTI has been
shown to have an EC50 for farnesyltransferase of 0.7 nM and for
geranylgeranyltransferase of N30 μM [17]. For our experiments in mice
(Figs. 6 and 7), we used the maximal dose possible in order to increase
the likelihood of observing an effect. For L-744,832 we used the
highest dose that themice could tolerate (unpublished results) and for
ABT-100 we used the highest dose that could be reliably dissolved.
Future experiments will be necessary to determine if lower doses of
the drugs are effective. However, given that both FTIs showed similar
efﬁcacy and that ABT-100 has demonstrated N100,000-fold selectivity
for farnesyltransferase inhibition over geranylgeranyltransferase [17],
it is most likely that the effects we have observed are due to
farnesyltransferase inhibition.
The farnesylated protein or proteins that are the functional target
of FTI treatment are not known. Up to 17 proteins are farnesylated
within the cell and several of them are known to be involved in
lymphocyte signaling [1]. Interestingly, transgenic mice that express
dominant negative H-Ras show delayed rejection of skin allografts
that are fully mismatched at MHC class I and II [33]. This observation
suggests that H-Ras inhibition may be involved in the action of FTIs
during allograft rejection. However, the inhibition of cytokine
secretion by FTI treatment does not appear to involve Ras inhibition
[21]. Therefore, it appears that some combination of farnesylated
proteins are the likely targets of FTI inhibition, as has been shown for
the anti-neoplastic activity of these drugs [1].
5.2. FTIs block cytokine production and cytokine-induced proliferation in
T cells
The ability of ABT-100 and L-744,832 to block secretion of
cytokines provides a possible mechanism for their speciﬁc immuno-
suppression activity. ABT-100 prevented secretion of IFN-γ, IL-2, IL-4,
and TNF-α from naïve T cells, extending the previous observations
that this FTI blocks secretion of IFN-γ and IL-2 frommurine Th1 clones
and secretion of IL-4 and IL-5 from murine Th2 clones [21]. We
conﬁrmed that FTIs were blocking cytokine production, and not
simply killing the cytokine-producing cells, by measuring cell viability
and by directly measuring cytokine synthesis within viable T cells
(Fig. 2). In addition to affecting CD4+ T cells, we have demonstrated
that ABT-100 can block secretion of TNF-α and IFN-γ from naïve CD8+
T cells (Figs. 1 and 2). This result is consistent with other observations
that TNF-α secretion can be blocked by FTIs both in vitro and in vivo
[18,20]. A less robust, but still signiﬁcant, inhibition of cytokine
secretionwas seenwhen allogeneic stimulator cells were used instead
of anti-CD3 and anti-CD28 antibodies (Fig. 4). Our further observation
that the mitogenic response of T cells to IL-2 is blocked by ABT-100
(Fig. 5b) indicates that the effects of cytokines on target cells may also
be blocked by FTIs. The block in proliferation is not mediated by
preventing the expression of high afﬁnity IL-2 receptors on activated T
cells, which we have found is unaffected by FTI treatment (unpub-
lished results). This observation is consistent with previous results
showing that ABT-100 does not effect expression of CD25 or other
activation markers on phytohemagglutinin-activated human periph-
eral blood mononuclear cells [24]. Together, our results show that FTIs
may have several effects on immune responses by modulating the
production of cytokines from a variety of cell types and the mitogenic
responses of cells to cytokines.
Fig. 7. Effects of L-744,832 on skin allograft rejection in a secondary alloreactive
response. Skin allografts were performed on B6 mice that had previously rejected a
bm12 graft approximately 4 weeks earlier. Seven of the recipient mice were left
untreated and 6 of the mice were treated with 40 mg/kg/day L-744,832 i.v. for 7 days
following the transplant.
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5.3. FTIs block proliferation of alloreactive T cells in MLCs
FTI treatment was found to block alloreactive cell proliferation in
both CD4+ and CD8+ T cells. Using BALB/c stimulator cells mismatched
at both class I and II MHC, ABT-100 was found to inhibit proliferation
by up to 85% (Fig. 5a). This provides clear evidence that the effects of
FTI treatment on cytokine secretion can delay an alloreactive immune
response and that the target of FTI action is the alloreactive T cell.
While the in vitro results do not preclude additional effects on the
recognition or effector phases of allorejection, a principal target of FTI
action appears to be the expansion phase. Proliferation of T cells under
these conditions is dependent on the mitogenic activity of cytokines;
we also found that T cell proliferation induced by IL-2 was blocked by
ABT-100 (Fig. 5b). We conclude that FTIs can affect both the secretion
of cytokines and their mitogenic stimulation of lymphocytes.
5.4. FTI treatment can delay alloreactive rejection in vivo
Treatment with either ABT-100 or L-744,832 delayed rejection of
class II MHC-disparate primary allografts (Fig. 6), directly demonstrat-
ing that FTIs can affect immune responses in vivo. Our results indicate
that FTIs may delay the expansion of CD4+ T cells once primed to
alloantigens by affecting cytokine secretion. By delaying the expan-
sion of the alloreactive T cells (Fig. 5), FTIs can slow the rejection of
primary allografts but do not affect secondary rejection (Fig. 7),
because the expansion of alloreactive clones has already occurred.
FTIs may also affect priming of the alloreactive immune response.
Priming of CD4+ T cells to MHC class II alloantigens involves several
steps, including the direct pathway of antigen presentation, recogni-
tion of MHC by CD4+ T cells, and activation of alloreactive T cells. Our
results from in vitro assays indicate that FTIs can block the cytokine
secretion that is involved in both the proliferation and differentiation
of alloreactive T cells after they have been primed. While we cannot
exclude possible effects of FTIs on antigen presentation or recognition
of alloantigens, the effects of FTIs on cytokine secretion are sufﬁcient
to explain the delay in allograft rejection.
5.5. Possible mechanisms of FTI action in allograft rejection
We chose a stringent model of MHC class II-mediated skin allograft
rejection because it had previously been shown to be dependent on
the secretion of a single cytokine, IFN-γ. B6 mice deﬁcient in IFN-γ or
treated with anti-IFN-γ antibodies are not capable of rejecting bm12
allografts, although they exhibit normal allorejection of class I
mismatched and fully mismatched grafts [34,35]. We demonstrated
that treatment with either ABT-100 or L-744,832 can delay bm12 graft
rejection in mice (Fig. 5). Therefore, we can conclude that FTI
treatment affects MHC II allorecognition and the activation of naïve
CD4+ T cells. We provide two possible mechanisms for this activity
of xFTIs involving IFN-γ. By blocking the secretion of IFN-γ from
activated naïve CD4+ T cells, FTIs may prevent the generation of a
proinﬂammatory environment and the IFN-γ-dependent secretion of
the Mig chemokine, which is also required for bm12 graft rejection in
B6 mice [36]. Second, FTIs may block the effects of IFN-γ and other
cytokines on the proliferation and/or survival of effector cells, as we
found for IL-2 (Fig. 5b).
It is likely that FTI treatment can affect other cytokines in addition
to those measured in this study. We demonstrated that FTI treatment
affected the Th2 cytokine, IL-4 (Fig. 1). Class II mismatched graft
rejection involves secretion of both IL-4 and IL-5 by Th2 cells [37,38]. A
third possible mechanism of action of FTIs on graft rejection involves
these Th2 cytokines. FTI treatment has the potential to affect the initial
coordination of the alloreactive response by stimulated naïve T cells
and alter their differentiation into Th1, Th2, and Treg cells. Inhibition
of Ras has been shown to increase FoxP3 expression in a human T cell
line [39], suggesting that FTI treatment could increase the number of
Treg cells induced during an immune response, presumably at the
expense of Th1 or Th2 cells. To determine if FTI treatment affects the
balance of Th1, Th2, and Treg cells generated, future studies will be
necessary to measure the effects of FTIs on cytokine production in vivo
and the generation of allospeciﬁc effector cells in graft-draining lymph
nodes.
Although several mechanisms may be involved in delaying
allograft rejection, our results suggest that the block in IFN-γ
secretion may be the most critical. The observation that second set
rejection was not affected by L-744,832 treatment (Fig. 7) demon-
strated that, after CD4+ T cells had been primed to the MHC II
alloantigen, the FTI no longer signiﬁcantly delayed the rejection
process. This observation is similar to that seen in IFN-γ knockout
mice that readily reject bm12 skin allografts only after priming to the
alloantigen [34]. The ability of FTI-treated mice to rapidly reject
second set grafts demonstrates that FTI treatment does not block the
effector mechanisms responsible for tissue cytotoxicity, including
lymphocyte migration and the production of proinﬂammatory
cytokines within the skin graft. Our results suggest that once an
alloreactive response had taken place during the primary rejection,
treatment with FTIs was unable to delay the strong allorejection
response of the primed effector T cells. This observation may suggest
that FTIs would be less useful to treat ongoing alloreactive immune
responses than as preventative therapy.
5.6. Implications
Our results have particular implications for the treatment of
malignancies by hematopoietic stem cell (HSC) transplantation and
the induction of tolerance following solid organ transplantation. By
including an FTI in the preparative or maintenance phases of HSC
therapy, we suggest that it might be possible to utilize both the direct
anti-neoplastic and the potential graft versus host disease inhibitory
activities of an FTI to improve outcomes. Through similar immuno-
modulatory mechanisms, it may be possible to use FTIs to delay
allorejection and induce tolerance following solid organ transplantation.
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